153 related articles for article (PubMed ID: 11396161)
1. Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract.
Hejna M; Hamilton G; Brodowicz T; Haberl I; Fiebiger WC; Scheithauer W; Virgolini I; Köstler WJ; Oberhuber G; Raderer M
Anticancer Res; 2001; 21(2A):1183-7. PubMed ID: 11396161
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide control of cyclic adenosine 3':5'-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture.
Laburthe M; Rousset M; Chevalier G; Boissard C; Dupont C; Zweibaum A; Rosselin G
Cancer Res; 1980 Jul; 40(7):2529-33. PubMed ID: 6248206
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentration of selected neuropeptides in patients suffering from psoriasis.
Reich A; Orda A; Wiśnicka B; Szepietowski JC
Exp Dermatol; 2007 May; 16(5):421-8. PubMed ID: 17437485
[TBL] [Abstract][Full Text] [Related]
4. Effect of vasoactive intestinal peptide on gastric adenocarcinoma.
Li GH; Qian W; Song GQ; Hou XH
J Gastroenterol Hepatol; 2007 Aug; 22(8):1328-35. PubMed ID: 17559364
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of transforming growth factor alpha in gastrointestinal cancer patients.
Moskal TL; Huang S; Ellis LM; Fritsche HA; Chakrabarty S
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):127-31. PubMed ID: 7742720
[TBL] [Abstract][Full Text] [Related]
6. Increased fasting serum levels of growth hormone and gastrin in patients with gastric and large bowel cancer.
Triantafillidis JK; Merikas E; Govosdis V; Konstandellou E; Cheracakis P; Barbatzas C; Tzourmakliotis D; Peros G
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cclvi-cclx. PubMed ID: 15244195
[TBL] [Abstract][Full Text] [Related]
7. [Vasoactive intestinal peptide expression and its clinical significance in gastric adenocarcinoma].
Chen H; Cen P; Li JQ; Lin YG; Jiang HX; Tang GD; Zang N; Feng ZB; Su QJ; Xiao X
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Dec; 22(6):452-4. PubMed ID: 19544643
[TBL] [Abstract][Full Text] [Related]
8. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma.
De Vita F; Orditura M; Lieto E; Infusino S; Morgillo F; Martinelli E; Castellano P; Romano C; Ciardiello F; Catalano G; Pignatelli C; Galizia G
Cancer; 2004 Jan; 100(2):270-8. PubMed ID: 14716760
[TBL] [Abstract][Full Text] [Related]
9. Localization of a vasoactive intestinal peptide-producing tumor with selective venous sampling.
Smith FR; Rogers AI
Am J Gastroenterol; 1980 Sep; 74(3):282-4. PubMed ID: 7468568
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of cell proliferation and C-myc cancer protein expression in human colon adenocarcinoma cell line HT29 with VIP-131I-ASON].
Ou X; Tan T; Li Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Oct; 23(5):1096-100. PubMed ID: 17121362
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR.
Clarke LE; Leitzel K; Smith J; Ali SM; Lipton A
Int J Oncol; 2003 Feb; 22(2):425-30. PubMed ID: 12527944
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
Koopmann J; Fedarko NS; Jain A; Maitra A; Iacobuzio-Donahue C; Rahman A; Hruban RH; Yeo CJ; Goggins M
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):487-91. PubMed ID: 15006928
[TBL] [Abstract][Full Text] [Related]
13. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition by VIP of the proliferation of pancreatic cancer cells].
Yao CZ
Zhonghua Wai Ke Za Zhi; 1989 Jan; 27(1):42-4, 62. PubMed ID: 2550185
[TBL] [Abstract][Full Text] [Related]
15. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and its relationship to tumor stage in colorectal carcinoma: an immunohistochemical study.
Hirayasu Y; Oya M; Okuyama T; Kiumi F; Ueda Y
J Gastroenterol; 2002; 37(5):336-44. PubMed ID: 12051532
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma thrombomodulin in cancer patients.
Lindahl AK; Boffa MC; Abildgaard U
Thromb Haemost; 1993 Feb; 69(2):112-4. PubMed ID: 8384380
[TBL] [Abstract][Full Text] [Related]
19. Hormonal regulation of adenylate cyclase activity in circulating lymphocytes and its interrelationship with hormone sensitivity of tumor tissue in colorectal cancer patients.
Berstein LM; Pravosudov IV; Kryukova OG
Neoplasma; 1995; 42(2):57-61. PubMed ID: 7617078
[TBL] [Abstract][Full Text] [Related]
20. VIP and calcitonin-producing pancreatic neuroendocrine tumor with watery diarrhea: clinicopathological features and the effect of somatostatin analogue.
Kon T; Wada R; Suzuki R; Nakayama Y; Ebina Y; Yagihashi S
JOP; 2012 Mar; 13(2):226-30. PubMed ID: 22406608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
